Press Releases

Year

May 7, 2026

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial

May 4, 2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

April 17, 2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

March 18, 2026

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial

March 16, 2026

4DMT to Participate in Upcoming Investor Meetings

EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

February 19, 2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

February 13, 2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

February 9, 2026

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients

January 16, 2026

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to

January 7, 2026

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 4D-150 PRISM wet AMD 2-year Phase 2b data expected mid-2026 4D-150 DME global

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page

About 4DMT

Navigation

Location